Healthcare Private Placement and M&A Transactions Review Week Ending August 6, 2023

CG Oncology: The company raised $105 million of Series F venture funding in a deal led by Foresite Capital Management and TCG Crossover Management on August 2, 2023, putting the company’s pre-money valuation at $520 million. Ally Bridge Group, Decheng Capital, Longitude Capital, Acorn Bioventures, Malin Corporation, Avidity Partners, BVF Partners, Janus Henderson Investors, and RA Capital Management also participated in the round. The company is an operator of a clinical-stage biopharmaceutical agency intended to develop oncolytic immunotherapy for patients with advanced cancer.

Tisento Therapeutics: The company raised $81 million of Series A venture funding from Cyclerion Therapeutics, Sanofi Ventures and J. Wood Capital Advisors on August 1, 2023, putting the company’s pre-money valuation at $35 million. The Invus Group, Venrock and Polaris Partners and other undisclosed investors also participated in the round. The company is a developer of medicine intended to treat diseases with significant unmet medical needs.

Aulos: The company raised $60 million of Series A venture funding from Apple Tree Partners (ATP) on August 1, 2023, putting the company’s pre-money valuation at $28 million. The company is an operator of a biotechnology business intended to develop pharmaceutical preparations for the treatment of cancer.

Chemify: The company raised $43 million of venture funding in a deal led by Triatomic Capital on August 2, 2023, putting the company’s pre-money valuation at $51.1 million. Horizons Ventures , Possible Ventures, and 6 other investors also participated in the round. The company is a developer of a chemical digitization platform intended to run chemical code for drug discovery, chemical synthesis, and materials discovery.

MarvelBiome: The company raised $10 million of venture funding from undisclosed investors on August 2, 2023. The company is a developer of a biopharmaceutical technology designed to harness the power of microbes for treating various human diseases.

Redona Therapeutics: The company raised $6 million of venture funding in the form of convertible debt from undisclosed investors on July 31, 2023. The company is a developer of RNA drugs designed to treat cancer and other human diseases.

Luminary Therapeutics: The company raised $2.4 million of venture funding in the form of SAFE NOTES from Myeloma Investment Fund and other undisclosed investors on August 2, 2023. The company is a developer of cell therapy platform designed for cancer and autoimmune diseases.

EQRx / Revolution Medicines: The company reached a definitive agreement to be acquired by Revolution Medicines for approximately $1.1 billion on August 1, 2023. EQRx Inc is a biotechnology company.

KZ1 / Kannaway: The company was acquired by Kannaway, a subsidiary of Medical Marijuana, for $5 million on August 1, 2023.. KZ1 is a producer of liquid multi-botanical dietary supplements based in West Palm Beach, Florida.

Aptamer Group / Individual Investors: The company reached a definitive agreement to be acquired by an Mr. Andrew Rapson, Dr Adam Hargreaves, Mr.Dean Fielding , Miss Angela Hildreth, Dr John Richards, Dr Rob Quinn, Dr Ian Gilham and Dr Ian Gilham for GBP 3.6 million on July 31, 2023. Aptamer Group PLC provides Optimer binders for use in research, diagnostics and therapeutics.

KOTAI Biotechnologies / Sanyo Trading Co.: The company was acquired by Sanyo Trading Co.for an undisclosed amount on August 1, 2023. KOTAI Biotechnologies is a developer of a structural modeling and analysis platform for immune cell receptors designed to aid in drug discovery.